Cargando…

An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature

BACKGROUND: Emerging evidences have indicated that the aberrant liquid–liquid phase separation (LLPS) leads to the dysfunction of biomolecular condensates, thereby contributing to the tumorigenesis and progression. Nevertheless, it remains unclear whether or how the LLPS of specific molecules affect...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Jianglin, Wu, Zhipeng, Qiu, Yue, Wang, Xuan, Jiang, Xiaobing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800244/
https://www.ncbi.nlm.nih.gov/pubmed/35093128
http://dx.doi.org/10.1186/s12967-022-03266-1
_version_ 1784642218336714752
author Zheng, Jianglin
Wu, Zhipeng
Qiu, Yue
Wang, Xuan
Jiang, Xiaobing
author_facet Zheng, Jianglin
Wu, Zhipeng
Qiu, Yue
Wang, Xuan
Jiang, Xiaobing
author_sort Zheng, Jianglin
collection PubMed
description BACKGROUND: Emerging evidences have indicated that the aberrant liquid–liquid phase separation (LLPS) leads to the dysfunction of biomolecular condensates, thereby contributing to the tumorigenesis and progression. Nevertheless, it remains unclear whether or how the LLPS of specific molecules affects the prognosis and tumor immune microenvironment (TIME) of patients with lower-grade glioma (LGG). METHODS: We integrated the transcriptome information of 3585 LLPS-related genes to comprehensively evaluate the LLPS patterns of 423 patients with LGG in The Cancer Genome Atlas (TCGA) cohort. Then, we systematically demonstrated the differences among four LLPS subtypes based on multi-omics analyses. In addition, we constructed the LLPS-related prognostic risk score (LPRS) for individualized integrative assessment. RESULTS: Based on the expression profiles of 85 scaffolds, 355 regulators, and 3145 clients in LGG, we identified four LLPS subtypes, namely LS1, LS2, LS3 and LS4. We confirmed that there were significant differences in prognosis, clinicopathological features, cancer hallmarks, genomic alterations, TIME patterns and immunotherapeutic responses among four LLPS subtypes. In addition, a prognostic signature called LPRS was constructed for individualized integrative assessment. LPRS exhibited a robust predictive capacity for prognosis of LGG patients in multiple cohorts. Moreover, LPRS was found to be correlated with clinicopathological features, cancer hallmarks, genomic alterations and TIME patterns of LGG patients. The predictive power of LPRS in response to immune checkpoint inhibitor (ICI) therapy was also prominent. CONCLUSIONS: This study provided a novel classification of LGG patients based on LLPS. The constructed LPRS might facilitate individualized prognosis prediction and better immunotherapy options for LGG patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03266-1.
format Online
Article
Text
id pubmed-8800244
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88002442022-02-02 An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature Zheng, Jianglin Wu, Zhipeng Qiu, Yue Wang, Xuan Jiang, Xiaobing J Transl Med Research BACKGROUND: Emerging evidences have indicated that the aberrant liquid–liquid phase separation (LLPS) leads to the dysfunction of biomolecular condensates, thereby contributing to the tumorigenesis and progression. Nevertheless, it remains unclear whether or how the LLPS of specific molecules affects the prognosis and tumor immune microenvironment (TIME) of patients with lower-grade glioma (LGG). METHODS: We integrated the transcriptome information of 3585 LLPS-related genes to comprehensively evaluate the LLPS patterns of 423 patients with LGG in The Cancer Genome Atlas (TCGA) cohort. Then, we systematically demonstrated the differences among four LLPS subtypes based on multi-omics analyses. In addition, we constructed the LLPS-related prognostic risk score (LPRS) for individualized integrative assessment. RESULTS: Based on the expression profiles of 85 scaffolds, 355 regulators, and 3145 clients in LGG, we identified four LLPS subtypes, namely LS1, LS2, LS3 and LS4. We confirmed that there were significant differences in prognosis, clinicopathological features, cancer hallmarks, genomic alterations, TIME patterns and immunotherapeutic responses among four LLPS subtypes. In addition, a prognostic signature called LPRS was constructed for individualized integrative assessment. LPRS exhibited a robust predictive capacity for prognosis of LGG patients in multiple cohorts. Moreover, LPRS was found to be correlated with clinicopathological features, cancer hallmarks, genomic alterations and TIME patterns of LGG patients. The predictive power of LPRS in response to immune checkpoint inhibitor (ICI) therapy was also prominent. CONCLUSIONS: This study provided a novel classification of LGG patients based on LLPS. The constructed LPRS might facilitate individualized prognosis prediction and better immunotherapy options for LGG patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-022-03266-1. BioMed Central 2022-01-29 /pmc/articles/PMC8800244/ /pubmed/35093128 http://dx.doi.org/10.1186/s12967-022-03266-1 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zheng, Jianglin
Wu, Zhipeng
Qiu, Yue
Wang, Xuan
Jiang, Xiaobing
An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature
title An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature
title_full An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature
title_fullStr An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature
title_full_unstemmed An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature
title_short An integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature
title_sort integrative multi-omics analysis based on liquid–liquid phase separation delineates distinct subtypes of lower-grade glioma and identifies a prognostic signature
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8800244/
https://www.ncbi.nlm.nih.gov/pubmed/35093128
http://dx.doi.org/10.1186/s12967-022-03266-1
work_keys_str_mv AT zhengjianglin anintegrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT wuzhipeng anintegrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT qiuyue anintegrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT wangxuan anintegrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT jiangxiaobing anintegrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT zhengjianglin integrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT wuzhipeng integrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT qiuyue integrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT wangxuan integrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature
AT jiangxiaobing integrativemultiomicsanalysisbasedonliquidliquidphaseseparationdelineatesdistinctsubtypesoflowergradegliomaandidentifiesaprognosticsignature